Hepatitis C inhibitor tri-peptides

Details Hepatitis C inhibitor tri-peptides Hepatitis C inhibitor tri-peptides

2008-03-05

2010-10-26

Powers, Fiona T (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S259500, C514S260100, C514S266400, C514S269000, C514S273000, C544S242000, C544S283000, C544S287000, C544S298000, C544S304000

Reissue Patent

active

RE041894

ABSTRACT:
Racemates, diastereoisomers and optical isomers of a compound of formula (I):whereinB is H, a C6or C10aryl, C7-16aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C1-6alkyl; C1-6alkoxy; C1-6alkanoyl; hydroxy; hydroxy-alkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6alkyl; amido; or (lower alkyl)amide; orB is an acyl derivative of formula R4—C(O)—; a carboxyl of formula R4—O—C(O)—; an amide of formula R4—N(R5)—C(O)—; a thioamide of formula R4—N(R5)—C(S)—; or a sulfonyl of formula R4—SO2; R5is H or C1-6alkyl; andY is H or C1-6alkyl;R3is C3-7cycloalkyl, or C4-10alkylcycloalkyl, all optionally substituted with hydroxy, C1-6alkoxy, C1-6thioalkyl, amido, (lower alkyl)amido, C6or C10aryl, or C7-16aralkyl;R2is CH2—R20, NH—R20, O—R20or S—R20, wherein R20is a saturated or unsaturated C3-7cycloalkyl or C4-10(alkylcycloalkyl), all of which being optionally mono-, di- or tri-substituted with R21,or R20is a C6or C10aryl or C7-14aralkyl optionally substituted, or R20is Het or (lower alkyl)-Het, both optionally substituted, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C6or C10aryl, C7-14aralkyl or Het, said aryl, aralkyl or Het being optionally substituted; andR1is H; C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, or C2-6alkynyl, all optionally substituted with halogen; or a pharmaceutically acceptable salt or ester thereof.

REFERENCES:
patent: 6329417 (2001-12-01), Llinas-Brunet et al.
patent: 6410531 (2002-06-01), Llinas-Brunet et al.
patent: 6420380 (2002-07-01), Llinas-Brunet et al.
patent: 6534523 (2003-03-01), Llinas-Brunet et al.
patent: 6919423 (2005-07-01), Llinas-Brunet
patent: 7091184 (2006-08-01), Llinas-Brunet et al.
patent: RE40525 (2008-09-01), Llinas-Brunet et al.
patent: 196 00 034 (1997-07-01), None
patent: WO 98 17679 (1998-04-01), None
patent: WO 1998 17679 (1998-04-01), None
patent: WO 99 07733 (1999-02-01), None
patent: WO 1999 07733 (1999-02-01), None
Gaucher, et al; “Palladium (O) Catalyzed Tandem Alkylation and SN' Cyclization . . . ” Tetrahedron Letters, 36(17): 2979-2982 (1995).
Fliche, et al; “Enantioselective synthesis of (1R, 2S) dehydrocoronamic acids” Synthetic Communications, 24(20): 2873-2876 (1994).
Chen, et al; “Chirally selective hydrolysis of D, L amino acid esters by alkaline protease” J. Chem, Soc., Chem. Commun. 20:1514-1516 (1986).
Chen, et al; “Kinetic resolution of esters of amino acids in t-butanol containing 5% water catalyzed by a stable industrial alkaline protease” Chirality 6: 572-576 (1994).
Llinas-Brunet, M. et al; “Peptide-based inhibitors of the hepatitis C virus serine protease” Bioorganic & Medicinal Chemistry Letters, 8(13): 1713-1718 (1998).
Ogawa, T. et al; “2,3-Methanophenylalanine and .Alpha., .Beta.-Dehydrophenylalanine Derivatives as Chymotryspin Inhibitor” Pept. Chem. 27: 379-382 (1990).
Gershonov et al; “1-Aminocyclobutanecarboxylic acid derivatives as novel structural elements in bioactive peptides: application to tufsin analogs”; Journal of Medicinal Chemistry, vol. 39, No. 24, 1996, p. 4833-4843.

Affiliated with

Also associated with

Rating

Hepatitis C inhibitor tri-peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hepatitis C inhibitor tri-peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C inhibitor tri-peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4158824